Incyte Corporation (INCY) EBITDA Margin: 34.24%
Is Incyte Corporation’s EBITDA margin high or low?
Incyte Corporation's EBITDA margin of 34.24% is 104% above its 5-year average of 16.80%, near the high end of its 5-year range (-6.68%–34.24%).
As of Sunday, June 21, 2026. 56.13% above its 12-month average of 21.93%.
INCY EBITDA Margin Chart
INCY Average EBITDA Margin Chart
INCY Current vs Average EBITDA Margin Chart
INCY EBITDA Margin Metrics
EBITDA MARGIN
34.24%
EBITDA MARGIN AVG TTM
21.93%
EBITDA MARGIN AVG 3Y
21.60%
EBITDA MARGIN AVG 5Y
16.80%
EBITDA MARGIN AVG 10Y
13.65%
EBITDA MARGIN AVG 15Y
12.37%
EBITDA MARGIN AVG 20Y
-22.12%
CURRENT VS TTM AVG
+56.13%
CURRENT VS 3Y AVG
+58.52%
CURRENT VS 5Y AVG
+103.77%
CURRENT VS 10Y AVG
+150.86%
CURRENT VS 15Y AVG
+176.74%
CURRENT VS 20Y AVG
+254.79%
INCY Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 34.24% | 21.93% | 21.60% | 16.80% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 14.43% | 14.18% | 13.98% | 17.86% |
| Viatris Inc. (VTRS)vs › | $17.90B | -2.77% | 8.18% | 19.68% | 20.07% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 26.94% | 28.13% | 26.95% | 24.72% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 57.15% | 57.33% | 56.99% | 52.54% |
| BioNTech SE (BNTX)vs › | $22.98B | -22.78% | -18.06% | 18.90% | 22.14% |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 30.67% | 31.14% | 31.31% | 30.59% |
| Waters Corporation (WAT)vs › | $23.17B | 31.97% | 33.50% | 33.77% | 33.93% |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 38.96% | 36.94% | 31.27% | 30.34% |
Margin Comparison
Gross Margin
92.5%
EBITDA Margin
34.2%
Operating Margin
27.1%
Net Margin
26.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Incyte Corporation EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation EBITDA Margin FAQ
- What is the EBITDA margin for Incyte Corporation (INCY)?
- The EBITDA margin for INCY stock is 34.24%.
- Is Incyte Corporation's EBITDA margin high or low?
- Incyte Corporation's EBITDA margin of 34.24% is 104% above its 5-year average of 16.80%, near the high end of its 5-year range (-6.68%–34.24%).
- What is the TTM average EBITDA margin for Incyte Corporation (INCY)?
- The TTM average EBITDA margin for INCY stock is 21.93%.
- What is the 3Y average EBITDA margin for Incyte Corporation (INCY)?
- The 3Y average EBITDA margin for INCY stock is 21.60%.
- What is the 5Y average EBITDA margin for Incyte Corporation (INCY)?
- The 5Y average EBITDA margin for INCY stock is 16.80%.
- What is the 10Y average EBITDA margin for Incyte Corporation (INCY)?
- The 10Y average EBITDA margin for INCY stock is 13.65%.
- What is the 15Y average EBITDA margin for Incyte Corporation (INCY)?
- The 15Y average EBITDA margin for INCY stock is 12.37%.
- What is the 20Y average EBITDA margin for Incyte Corporation (INCY)?
- The 20Y average EBITDA margin for INCY stock is -22.12%.
Incyte Corporation EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 34.24% |
| 2024-12-31 | 9.62% |
| 2023-12-31 | 24.88% |
| 2022-12-31 | 17.66% |
| 2021-12-31 | 21.10% |
| 2020-12-31 | -6.68% |
| 2019-12-31 | 25.16% |
| 2018-12-31 | 9.13% |
| 2017-12-31 | -16.48% |
| 2016-12-31 | 18.50% |
| 2015-12-31 | 13.01% |
| 2014-12-31 | 7.76% |
| 2013-12-31 | -4.22% |
| 2012-12-31 | 10.74% |
| 2011-12-31 | -122.53% |
| 2010-12-31 | 21.17% |
| 2009-12-31 | -1328.42% |
| 2008-12-31 | -3731.00% |
| 2007-12-31 | -209.98% |
| 2006-12-31 | -251.25% |
| 2005-12-31 | -1180.12% |
| 2004-12-31 | -953.91% |
| 2003-12-31 | -239.11% |
| 2002-12-31 | -115.76% |
| 2001-12-31 | -7.77% |
| 2000-12-31 | -14.29% |
| 1999-12-31 | -1.46% |
| 1998-12-31 | 22.26% |
| 1997-12-31 | 15.78% |
| 1996-12-31 | -5.73% |
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury